- $31.36m
- $24.46m
- $7.53m
Brief: Evaxion Presents A New Source Of Ai-Derived Immunotherapeutic Targets Strongly Associated With The Overall Survival Of Cancer Patients
U.S. STOCKS ON THE MOVE-Alibaba Group, TripAdvisor, MGM Resorts
U.S. STOCKS ON THE MOVE-Alphabet, Fox Corp, New York Times
U.S. STOCKS ON THE MOVE-Manchester United, Under Armour, Capri
Brief: Evaxion And Pantherna Announce Promising Preclinical Mrna Vaccine Data
U.S. STOCKS ON THE MOVE-Walt Disney, Personalis, Netflix
U.S. STOCKS ON THE MOVE- NextDecade, Eli Lilly, Norwegian
Evaxion Biotech gains as cancer therapy gets FDA's fast track tag
Brief: Evaxion Biotech A/S Receives FDA Fast-Track Designation For Personalized Cancer Immunotherapy
Refile: BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, Starbucks, ASLAN Pharma
U.S. STOCKS ON THE MOVE-Jasper Therapeutics, Blackstone, Mondelez
U.S. STOCKS ON THE MOVE-Horizon Global, Apple, PayPal Holdings
Brief: Evaxion Receives FDA Approval To Proceed With Clinical Phase 2b Study For EVX-01
Evaxion Biotech jumps on U.S. FDA nod for skin cancer therapy study
Evaxion surges on U.S. FDA nod for cancer therapy trial
Brief: Evaxion To Present A Full Clinical Readout On Two Personalized Cancer Immunotherapies In Q2 2023
Brief: Expres2ion Initiates Research Collaboration With Evaxion
Evaxion Biotech A/S reports results for the quarter ended in September - Earnings Summary
Evaxion Biotech up on trial data on cancer therapy